Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869276 | 0.90 | PARP1 (0.82) | PARP1PARP2CYP2D6CYP2B6POLB | |
| SCHEMBL15662552 | 0.90 | PARP1 (0.82) | PARP1PARP2CYP2D6CYP2B6POLB | |
| SCHEMBL15661579 | 0.89 | PARP1 (0.81) | PARP1PARP2POLBHTTESR2 | |
| SCHEMBL835366 | 0.88 | PARP2 (0.93) | PARP1PARP2POLBHTTESR2 | |
| SCHEMBL15661314 | 0.87 | PARP2 (1.00) | PARP1PARP2POLBHTTESR2 | |
| SCHEMBL1865261 | 0.87 | PARP1 (1.00) | PARP1PARP2CYP2D6CYP2B6POLB | |
| SCHEMBL1882438 | 0.86 | PARP2 (0.81) | PARP1PARP2POLBHTTESR2 | |
| SCHEMBL1882436 | 0.86 | PARP2 (0.81) | PARP1PARP2POLBHTTESR2 | |
| SCHEMBL6128731 | 0.86 | PARP2 (0.81) | PARP1PARP2POLBHTTESR2 | |
| SCHEMBL6128730 | 0.85 | PARP2 (0.80) | PARP1PARP2POLBHTTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454236-B1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-09-04 | — | — | EP | claimed |
| US-8877944-B2 | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-04 | — | — | US | claimed |
| EP-2600867-A1 | THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-12 | — | — | EP | claimed |
| US-20130129841-A1 | THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-05-23 | — | — | US | claimed |
| CN-103052390-A | Therapeutic combination comprising parp-1 inhibitor and anti-neoplastic agent | NERVIANO MEDICAL SCIENCES SRL | 2013-04-17 | — | — | CN | claimed |
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-27 | — | — | US | claimed |
| EP-2454236-A1 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-05-23 | — | — | EP | claimed |
| WO-2012016876-A1 | THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | claimed |
| WO-2011006794-A9 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | WO | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-27 | — | — | US | disclosed |
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-27 | — | — | US | disclosed |
| EP-2454236-A1 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-05-23 | — | — | EP | disclosed |
| WO-2012016876-A1 | THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011006794-A9 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011006794-A9 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129841-A1 | THERAPEUTIC COMBINATION COMPRISING A PARP-1 INHIBITOR AND AN ANTI-NEOPLASTIC AGENT | PARP1, PARP2, TOP1 | PARP1 1/4885PARP2 2/4885CYP2D6 1945/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PARP1 418/4885PARP2 422/4885CYP2D6 2582/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | PARP1 92/4885PARP2 108/4885CYP2D6 1194/4885 |
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885CYP2D6 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.